U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H10F3N3O4
Molecular Weight 317.2212
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NILUTAMIDE

SMILES

CC1(C)C(=O)N(c2ccc(c(c2)C(F)(F)F)N(=O)=O)C(=N1)O

InChI

InChIKey=XWXYUMMDTVBTOU-UHFFFAOYSA-N
InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207631Orig1s000lbl.pdf

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. The relative binding affinity of nilutamide at the androgen receptor is less than that of bicalutamide, but similar to that of hydroxuflutamide. Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. This blockade of androgen receptors may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis. Nilutamide is used in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2). Nilutamide is sold under the brand names Nilandron (US), Anandron (CA)).

CNS Activity

Curator's Comment:: Like flutamide and bicalutamide, nilutamide is able to cross the blood-brain-barrier and has central antiandrogen actions.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NILANDRON

Approved Use

Metastatic Prostate Cancer Nilutamide Tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2).

Launch Date

8.4300477E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.3 mg/L
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.3 mg/L
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
84 mg × h/L
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
49 h
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
56 h
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
DLT: Nausea, Vomiting...
Disc. AE: Hot flashes, Interstitial lung disease...
Dose limiting toxicities:
Nausea (7.5%)
Vomiting (7.5%)
AEs leading to
discontinuation/dose reduction:
Hot flashes (5.7%)
Interstitial lung disease (3.8%)
Visual disturbance NOS (1.9%)
Pruritus (1.9%)
Dizziness (1.9%)
Headache (1.9%)
Hepatic enzyme increased (1.9%)
Sources: Page: p.1075
13 g single, oral
Overdose
unhealthy, 79
n = 1
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 79
Sex: M
Population Size: 1
Sources:
Disc. AE: Vomiting, Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Vomiting (moderate)
Diarrhoea (moderate)
Sources:
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Disc. AE: Gastrointestinal disorders, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorders
Nausea
Vomiting
Malaise
Headache
Dizziness
Sources:
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Co-administed with::
leuprolide
Sources: Page: p.8
unhealthy
n = 209
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 209
Sources: Page: p.8
Disc. AE: Visual disturbances...
AEs leading to
discontinuation/dose reduction:
Visual disturbances (1 - 2)
Sources: Page: p.8
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.3
Disc. AE: Interstitial pneumonitis, Pulmonary fibrosis...
AEs leading to
discontinuation/dose reduction:
Interstitial pneumonitis (2%)
Pulmonary fibrosis (grade 5, rare)
Sources: Page: p.3
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.4
Disc. AE: Liver injury...
AEs leading to
discontinuation/dose reduction:
Liver injury (severe, rare)
Sources: Page: p.4
AEs

AEs

AESignificanceDosePopulation
Dizziness 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Headache 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Hepatic enzyme increased 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Pruritus 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Visual disturbance NOS 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Interstitial lung disease 3.8%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Hot flashes 5.7%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Nausea 7.5%
DLT
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Vomiting 7.5%
DLT
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Diarrhoea moderate
Disc. AE
13 g single, oral
Overdose
unhealthy, 79
n = 1
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 79
Sex: M
Population Size: 1
Sources:
Vomiting moderate
Disc. AE
13 g single, oral
Overdose
unhealthy, 79
n = 1
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 79
Sex: M
Population Size: 1
Sources:
Dizziness Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Gastrointestinal disorders Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Headache Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Malaise Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Nausea Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Vomiting Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Visual disturbances 1 - 2
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Co-administed with::
leuprolide
Sources: Page: p.8
unhealthy
n = 209
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 209
Sources: Page: p.8
Interstitial pneumonitis 2%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.3
Pulmonary fibrosis grade 5, rare
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.3
Liver injury severe, rare
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.4
PubMed

PubMed

TitleDatePubMed
Flare Associated with LHRH-Agonist Therapy.
2001
Androgen deprivation and other treatments for advanced prostate cancer.
2001
Therapeutic androgen receptor ligands.
2003
Major impact of hormonal therapy in localized prostate cancer--death can already be an exception.
2004 Dec
Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines.
2004 Jun
Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans.
2004 May-Jun
Monotherapy in advanced prostate cancer: an overview.
2004 Sep
Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience.
2005 Apr
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
2005 Aug
How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
2005 Feb
Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain.
2005 Feb 24
[From the finger to the eye!...].
2005 Jul
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Combined androgen blockade: the case for bicalutamide.
2005 Mar
Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy.
2005 Mar-Apr
Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives.
2005 Nov 15
Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
2005 Oct
Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro.
2005 Oct 1
Nontranscriptional regulation of cardiac repolarization currents by testosterone.
2005 Sep 20
Androgenic and antiandrogenic effects and expression of androgen receptor in mouse embryonic stem cells.
2006 Apr
Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3.
2006 Apr
The role of steroids in follicular growth.
2006 Apr 10
Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
2006 Aug
Ginsenoside Re, a main phytosterol of Panax ginseng, activates cardiac potassium channels via a nongenomic pathway of sex hormones.
2006 Dec
Metabolism of nilutamide in rat lung.
2006 Jan 12
GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
2006 Jun 1
Recent progress in hormonal therapy for advanced prostate cancer.
2006 May
Combined androgen blockade: an update.
2006 May
Bioactivation and hepatotoxicity of nitroaromatic drugs.
2006 Oct
[Keyrole of endocrinology in the victory against prostate cancer].
2006 Sep
Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptor.
2007 Feb 16
New therapeutic targets in the treatment of prostate cancer.
2007 Jan
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Antiandrogenic activity of pyrethroid pesticides and their metabolite in reporter gene assay.
2007 Jan
Screening of 397 chemicals and development of a quantitative structure--activity relationship model for androgen receptor antagonism.
2008 Apr
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
2008 Jan 24
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
2008 Jul 15
Delayed dark adaptation caused by nilutamide.
2008 Jun
Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide.
2008 Mar 27
A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
2008 Nov 5
FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects.
2008 Sep 24
Fulminant hepatic failure due to nilutamide hepatotoxicity.
2009 Apr
Fasting and cancer treatment in humans: A case series report.
2009 Dec 31
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
2009 Mar 10
Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway.
2010 Apr
The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.
2010 Apr 20
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
2010 Feb 24
Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor.
2010 Jan 26
Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells.
2010 Jun 3
Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice.
2010 Sep
Patents

Sample Use Guides

The recommended dosage is 300 mg once a day for 30 days, followed thereafter by 150 mg once a day. Nilutamide Tablets can be taken with or without food.
Route of Administration: Oral
In Vitro Use Guide
At concentrations expected in the human liver (110 uM), nilutamide inhibited hexobarbital hydroxylase, benzphetamine N-demethylase, benzo(a)pyrene hydroxylase and 7-ethoxycoumarin O-deethylase activities by 85, 40, 35 and 25%, respectively in human liver microsomes.
Name Type Language
NILUTAMIDE
EP   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
NILUTAMIDE [INN]
Common Name English
NILUTAMIDE [ORANGE BOOK]
Common Name English
5,5-DIMETHYL-3-(.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-4-NITRO-M-TOLYL)HYDANTOIN
Systematic Name English
2,4-IMIDAZOLIDINEDIONE, 5,5-DIMETHYL-3-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)-
Systematic Name English
NILUTAMIDE [EP MONOGRAPH]
Common Name English
NILUTAMIDE [USP MONOGRAPH]
Common Name English
NILUTAMIDE [MI]
Common Name English
RU 23908
Code English
NILUTAMIDE [MART.]
Common Name English
NSC-758683
Code English
NILUTAMIDE [VANDF]
Common Name English
RU-23908
Code English
NILUTAMIDE [USP-RS]
Common Name English
NILANDRON
Brand Name English
NILUTAMIDE [USAN]
Common Name English
NILUTAMIDE [WHO-DD]
Common Name English
Classification Tree Code System Code
LIVERTOX 686
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
NDF-RT N0000000243
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
NCI_THESAURUS C146993
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
WHO-VATC QL02BB02
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
WHO-ATC L02BB02
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
NDF-RT N0000175560
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
Code System Code Type Description
EPA CompTox
63612-50-0
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
MESH
C021277
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
NCI_THESAURUS
C1173
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
WIKIPEDIA
NILUTAMIDE
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
PUBCHEM
4493
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
MERCK INDEX
M7899
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL1274
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
EVMPD
SUB09291MIG
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
FDA UNII
51G6I8B902
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
DRUG BANK
DB00665
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
DRUG CENTRAL
1933
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
CAS
63612-50-0
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
INN
5755
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
USP_CATALOG
1463472
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY USP-RS
IUPHAR
2864
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY
RXCUI
31805
Created by admin on Fri Jun 25 21:19:59 UTC 2021 , Edited by admin on Fri Jun 25 21:19:59 UTC 2021
PRIMARY RxNorm